J Glob Antimicrob Resist. 2021 Jul 18:S2213-7165(21)00174-0. doi: 10.1016/j.jgar.2021.07.005. Online ahead of print.
OBJECTIVES: This study aimed to investigate the trends in serotypes and in vitro susceptibility of Streptococcus pneumoniae causing adult invasive pneumococcal disease (IPD) to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics from 2017 to 2020, following implementation of the 13-valent pneumococcal conjugate vaccine (PCV-13) and during the COVID-19 pandemic.
METHODS: During the study period, a total of 237 isolates of S. pneumoniae were collected from non-duplicate patients, covering 15% of IPD cases in Taiwan. Antimicrobial susceptibility testing was performed using the Sensititre® system (TREK Diagnostic Systems). A latex agglutination method (ImmuLex™ Pneumotest kit) was used to determine the serotypes.
RESULTS: The susceptibility rates were high for vancomycin (100%), teicoplanin (100%), and linezolid (100%), followed by ceftaroline (non-meningitis) (98.3%), moxifloxacin (94.9%), and quinupristin/dalfopristin (89.9%). The MIC50s and MIC90s of dalbavancin, telavancin, tedizolid, eravacycline, and omadacycline were generally low for the isolates. Non-vaccine serotype 23A was the top cause of IPD across the adult age. Isolates of serotype 15B were slightly fewer than those of PCV-13 serotypes in patients aged >65 years. The overall case-fatality rate was 15.2% (36/237) but was especially high for non-PCV-13 serotype 15B (21.4%, 3/14). The vaccine coverage was 44.7% for PCV-13 and 49.4% for 23-valent pneumococcal polysaccharide vaccine (PPSV-23), but was 57% for both PCV-13 and PPSV-23.
CONCLUSIONS: The incidence of IPD was stationary after PCV-13 introduction and only dramatically decreased in the COVID-19 pandemic in 2020. The MIC50s and MIC90s of dalbavancin, telavancin, tedizolid, eravacycline, omadacycline were generally low for S. pneumoniae causing adult IPD.